LLY
The global race for obesity market dominance reached a historic turning point this week as Eli Lilly and Company (NYSE: LLY) officially crossed the $1 trillion market capitalization threshold, cementing its status as the world’s most valuable healthcare entity. The milestone follows a stellar 2026 guidance report that projected
Novo Nordisk
As the first full week of 2026 unfolds, the pharmaceutical landscape is witnessing a seismic shift led by the Danish healthcare giant Novo Nordisk (NYSE: NVO). On January 5, 2026, the company officially launched the oral version of its blockbuster weight-loss drug, Wegovy, in the United States. This move marks
Eli Lilly
Eli Lilly and Company (NYSE: LLY) has once again sent ripples through the pharmaceutical world with the announcement of groundbreaking Phase 3 trial results for its investigational obesity drug, retatrutide. The data, particularly from the TRIUMPH-4 study, reveals unprecedented levels of weight loss and significant improvements in co-morbidities like knee
Hims & Hers Health
Hims & Hers Health (NYSE: HIMS) became a significant after-hours mover on Monday, November 3, 2025, following the release of its third-quarter 2025 financial results and the pivotal announcement of renewed discussions with Novo Nordisk A/S (NYSE: NVO) regarding the potential distribution of Wegovy. While the telehealth platform reported
Novo Nordisk
Copenhagen, Denmark – October 2, 2025 – Shares of Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) experienced a significant surge yesterday, October 1, 2025, following a pivotal upgrade from HSBC. The financial institution elevated Novo Nordisk's rating from "Hold" to "Buy," triggering a robust 6.6%